Skip to main content
ANAPTYSBIO, INC logo

ANAPTYSBIO, INC — Investor Relations & Filings

Ticker · ANAB ISIN · US0327241065 LEI · 529900HH4WQT03IG1A12 US Professional, scientific and technical activities
Open in API
Filings indexed 636 across all filing types
Latest filing 2017-11-07 Interim / Quarterly Rep…
Country US United States of America
Listing US ANAB

About ANAPTYSBIO, INC

https://www.anaptysbio.com/

AnaptysBio, Inc. is a clinical-stage biotechnology company that focuses on the discovery and development of innovative immunology therapeutics. The company specializes in advancing immune cell-modulating antibodies designed to treat autoimmune and inflammatory diseases. Its therapeutic candidates target key pathways in the immune system to address significant unmet medical needs for various patient populations.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q3 2017
2017-11-07 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 7, 2017, reporting the financial results for the three and nine months ended September 30, 2017. It specifically mentions that the financial results are announced via a press release attached as Exhibit 99.01. The document itself is short (4074 characters) and primarily serves as a notification of the earnings release rather than containing detailed financial statements or analysis. According to the rules, such a document that announces or attaches a press release of financial results without substantive financial data should be classified as an Earnings Release (ER).
2017-11-07 English
Major Shareholding Notification 2017
Major Shareholding Notification
2017-10-20 English
424B4
Capital/Financing Update Classification · 100% confidence The document is a detailed prospectus for a public offering of common stock, specifically a Form 424B4 filed pursuant to Rule 424(b)(4). It includes information about the offering size, underwriting details, risk factors, use of proceeds, dividend policy, capitalization, dilution, related party transactions, principal stockholders, description of capital stock, tax considerations, underwriting, legal matters, and expert opinions. The document is not a financial report, earnings release, management discussion, or any other type of corporate filing related to financial results or governance. Instead, it is a capital markets document related to the issuance of new shares and fundraising activities. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and content confirm it is the actual offering prospectus, not just an announcement or summary.
2017-10-13 English
Regulatory Filings 2017
Regulatory Filings
2017-10-13 English
S-1/A
Regulatory Filings Classification · 100% confidence The document is an S-1/A Registration Statement Amendment No. 1 filed with the SEC under the Securities Act of 1933. It includes detailed information about the company's business, offering details, risk factors, use of proceeds, capitalization, and other disclosures typical of a registration statement for an initial public offering or secondary offering. It is not a financial report, earnings release, or management discussion, but a regulatory filing to register securities for sale to the public. Therefore, it fits the category of Regulatory Filings (RNS). The document length is substantial (15,000 characters), and it is not merely an announcement or certification but the actual registration statement amendment filing.
2017-10-11 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.